Wednesday, October 26, 2016

WATCH YOUR WALLETS: ObamaCare Individual Plan Rate Hikes

(via USA Today)

1 comment:

  1. Humana (HUM) to Cover Sarepta (SRPT)'s Controversial DMD Drug But There's a Catch

    The FDA's controversial approval of Sarepta Therapeutics' (NASDAQ:SRPT) eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping has translated into a difficult path to insurance coverage.

    Humana says it will cover the $300K+ cost of therapy only for ambulatory DMD patients. Those who are wheelchair-bound or deteriorate to wheelchair status are apparently out of luck.

    Anthem (NYSE:ANTM) has declined to cover it at all because it considers eteplirsen experimental despite the OK from the FDA.

    Picking winners and losers in at it's finest...the system sucks. Should happen to their kids.